These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10681653)

  • 1. Pathophysiology and clinical importance of hyperhomocysteinemia: clinical intervention studies.
    Sunder-Plassmann G; Födinger M
    Miner Electrolyte Metab; 1999; 25(4-6):286-90. PubMed ID: 10681653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M;
    Clin Chem Lab Med; 2003 Nov; 41(11):1392-403. PubMed ID: 14656016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updating the relationship between hyperhomocysteinemia lowering therapy and cardiovascular events.
    Cheng X
    Cardiovasc Ther; 2013 Aug; 31(4):e19-26. PubMed ID: 23082962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperhomocysteinemia in chronic renal failure: alternative therapeutic strategies.
    Perna AF; Sepe I; Lanza D; Pollastro RM; De Santo NG; Ingrosso D
    J Ren Nutr; 2012 Jan; 22(1):191-4. PubMed ID: 22200441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.
    Clarke R; Armitage J
    Semin Thromb Hemost; 2000; 26(3):341-8. PubMed ID: 11011852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homocysteine and renal disease.
    van Guldener C; Robinson K
    Semin Thromb Hemost; 2000; 26(3):313-24. PubMed ID: 11011849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cellular and molecular mechanism of cardiovascular disease resulting from hyperhomocysteinemia].
    Gao L; Tang CS
    Sheng Li Ke Xue Jin Zhan; 2002 Oct; 33(4):335-8. PubMed ID: 12650071
    [No Abstract]   [Full Text] [Related]  

  • 9. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
    Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM
    Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients.
    Righetti M; Ferrario GM; Milani S; Serbelloni P; La Rosa L; Uccellini M; Sessa A
    Med Sci Monit; 2003 Apr; 9(4):PI19-24. PubMed ID: 12709680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperhomocysteinemia in renal diseases.
    Ferechide D; Radulescu D
    J Med Life; 2009; 2(1):53-9. PubMed ID: 20108491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Homocysteinemia and vascular disease--a new risk factor is born].
    Reis RP; Luís AS
    Rev Port Cardiol; 1999 May; 18(5):507-14. PubMed ID: 10418265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperhomocysteinemia: an additional cardiovascular risk factor.
    Fanapour PC; Yug B; Kochar MS
    WMJ; 1999 Dec; 98(8):51-4. PubMed ID: 10639897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homocysteine, B vitamins, and cardiovascular disease.
    Quinlivan EP; Gregory JF
    N Engl J Med; 2006 Jul; 355(2):206; author reply 209-11. PubMed ID: 16838446
    [No Abstract]   [Full Text] [Related]  

  • 15. [Risk factors for cardiovascular diseases: what is the role for homocysteine?].
    Bendini MG; Lanza GA; Mazza A; Giordano A; Leggio M; Menichini G; De Cristofaro R; Moriconi E; Cozzari L; Farina SM; Giordano G
    G Ital Cardiol (Rome); 2007 Mar; 8(3):148-60. PubMed ID: 17461357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Disturbances of homocysteine metabolism as a risk factor of cardiovascular diseases development: effect on prognosis and possibilities of correction with drugs].
    Shakhmatova OO; Komarov AL; Panchenko EP
    Kardiologiia; 2010; 50(1):42-50. PubMed ID: 20144157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homocysteine, B vitamins, and cardiovascular disease.
    de Craen AJ; Stott DJ; Westendorp RG
    N Engl J Med; 2006 Jul; 355(2):205-6; author reply 209-11. PubMed ID: 16837687
    [No Abstract]   [Full Text] [Related]  

  • 18. Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications.
    Perna AF; Ingrosso D; Castaldo P; De Santo NG; Galletti P; Zappia V
    Miner Electrolyte Metab; 1999; 25(1-2):95-9. PubMed ID: 10207268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
    Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS
    J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients].
    Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E
    Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.